The Dual Role of MicroRNAs in Colorectal Cancer Progression

Lei Ding, Zhenwei Lan, Xianhui Xiong, Hongshun Ao, Yingting Feng, Huan Gu, Min Yu, Qinghua CuiInternational Journal of Molecular Sciences 2018 · DOI

TL;DR

This review explores the complex, dual role of microRNAs (miRNAs) in colorectal cancer (CRC), highlighting how these small RNA molecules can act as both drivers (oncogenes) and suppressors of tumor development. Understanding these roles is crucial for developing new diagnostic biomarkers and therapeutic strategies for CRC.

What Problem Does This Paper Address?

Colorectal cancer (CRC) is a major global health challenge, responsible for significant incidence and mortality. While conventional treatments exist, they often come with severe side effects and resistance issues. The paper addresses the need for better understanding of the molecular mechanisms driving CRC progression to identify novel therapeutic targets and diagnostic tools. Specifically, it focuses on microRNAs (miRNAs), a class of small, non-coding RNAs that have emerged as critical regulators of gene expression and are increasingly implicated in various diseases, including cancer. The challenge lies in deciphering the precise, and often context-dependent, roles of these miRNAs in CRC, as they can either promote or inhibit tumor development.

Methods

This paper is a comprehensive review, not an experimental study. Therefore, it doesn't present novel experimental methods. Instead, it synthesizes and analyzes findings from numerous published research articles. The "methods" employed by the authors are:

  • Literature Review and Synthesis: The authors systematically searched and reviewed existing scientific literature on miRNAs and colorectal cancer.
  • Categorization and Analysis: They categorized miRNAs into two main groups based on their function in CRC: oncogenic (tumor-promoting) and tumor-suppressive (tumor-inhibiting).
  • Mechanism Elucidation: The review details the molecular mechanisms by which these miRNAs exert their effects, focusing on their interactions with target mRNAs and long non-coding RNAs (lncRNAs), and their downstream signaling pathways.
  • Biomarker and Therapeutic Target Identification: The authors highlight miRNAs that show promise as diagnostic biomarkers or therapeutic targets based on their expression patterns and functional roles in CRC.

Datasets

Not discussed in the paper. This is a review article that synthesizes existing research, rather than presenting new experimental data or analyses on specific datasets.

Key Insights and Ideas

  • The "Dual Role" Phenomenon: The most striking insight is that miRNAs are not simply "good" or "bad" in cancer. Their function as either an oncogene or a tumor suppressor is highly context-dependent, influenced by the specific cellular environment and the target genes they interact with.
  • miRNAs as Master Regulators: miRNAs act as post-transcriptional regulators, fine-tuning gene expression by degrading target mRNAs or inhibiting their translation. This makes them powerful controllers of complex cellular processes like proliferation, apoptosis, invasion, and metastasis.
  • miRNAs in Diagnostic and Prognostic Potential: Aberrant expression of specific miRNAs is frequently observed in CRC tissues and can correlate with disease stage, progression, and patient survival. This suggests their potential as valuable biomarkers for early detection, prognosis, and even predicting treatment response.
  • Therapeutic Avenues: The identification of specific miRNAs that drive CRC progression opens doors for therapeutic interventions, such as using anti-miRNA oligonucleotides (antagomirs) to inhibit oncogenic miRNAs or developing miRNA mimics to restore the function of tumor-suppressive miRNAs.
  • Complex Regulatory Networks: miRNAs don't act in isolation. They are part of intricate regulatory networks involving lncRNAs and various signaling pathways (e.g., Wnt/β-catenin, PI3K/Akt, TGF-β), making their study complex but also revealing deeper insights into CRC pathogenesis.

Key Results

The paper doesn't present quantitative results in the traditional sense, as it's a review. However, it highlights key findings from the literature:

  • Identification of Key Oncogenic miRNAs: Several miRNAs, including miR-21, miR-92a, miR-96, miR-135a/b, miR-155, miR-224, and miR-214, are consistently found to be upregulated in CRC and promote tumor growth, invasion, metastasis, and chemoresistance by targeting tumor suppressor genes.
  • Identification of Key Tumor-Suppressive miRNAs: Conversely, miRNAs like the let-7 family, miR-194, miR-143/145, miR-34a, miR-126, and miR-27b are often downregulated in CRC and inhibit tumor progression by targeting oncogenes.
  • Biomarker Potential Demonstrated: Studies cited show that specific miRNA expression profiles in blood or stool samples can distinguish CRC patients from healthy individuals and correlate with disease stage and prognosis.
  • Therapeutic Efficacy Suggested: Pre-clinical studies indicate that modulating miRNA levels (e.g., using anti-miRs or mimics) can impact CRC cell behavior and sensitivity to existing therapies.

Limitations and Future Work

  • Context Dependency: The primary limitation acknowledged is the context-dependent nature of miRNA function. What might be tumor-suppressive in one cellular context could be oncogenic in another, making it challenging to develop universal therapeutic strategies.
  • Complexity of Target Networks: The intricate web of miRNA targets and their interactions with other regulatory molecules (like lncRNAs) means that a complete understanding of their roles is still evolving.
  • Delivery Challenges: While miRNA-based therapeutics hold promise, efficient and targeted delivery to tumor cells remains a significant hurdle.
  • Clinical Translation: Despite promising pre-clinical data, translating miRNA research into effective clinical applications for CRC diagnosis and treatment requires further investigation and validation.

The authors suggest that future work should focus on:

  • Elucidating precise molecular mechanisms: Further research is needed to fully define the targets and pathways regulated by specific miRNAs in CRC.
  • Developing advanced delivery systems: Innovations in drug delivery are crucial for the successful clinical application of miRNA-based therapies.
  • Conducting large-scale clinical trials: Rigorous clinical studies are necessary to validate the diagnostic and therapeutic potential of miRNAs in CRC patients.
  • Exploring miRNA interactions with other cancer hallmarks: Understanding how miRNAs interplay with other aspects of cancer biology, such as the tumor microenvironment and immune evasion, is vital.

Summary updated

Abstract

Colorectal cancer (CRC) is responsible for one of the major cancer incidence and mortality worldwide. It is well known that MicroRNAs (miRNAs) play vital roles in maintaining the cell development and other physiological processes, as well as, the aberrant expression of numerous miRNAs involved in CRC progression. MiRNAs are a class of small, endogenous, non-coding, single-stranded RNAs that bind to the 3’-untranslated region (3′-UTR) complementary sequences of their target mRNA, resulting in mRNA degradation or inhibition of its translation as a post-transcriptional regulators. Moreover, miRNAs also can target the long non-coding RNA (lncRNA) to regulate the expression of its target genes involved in proliferation and metastasis of CRC. The functions of these dysregulated miRNAs appear to be context specific, with evidence of having a dual role in both oncogenes and tumor suppression depending on the cellular environment in which they are expressed. Therefore, the unique expression profiles of miRNAs relate to the diagnosis, prognosis, and therapeutic outcome in CRC. In this review, we focused on several oncogenic and tumor-suppressive miRNAs specific to CRC, and assess their functions to uncover the molecular mechanisms of tumor initiation and progression in CRC. These data promised that miRNAs can be used as early detection biomarkers and potential therapeutic target in CRC patients.
BibTeX
@article{ding2018dual,
  author = {Lei Ding and Zhenwei Lan and Xianhui Xiong and Hongshun Ao and Yingting Feng and Huan Gu and Min Yu and Qinghua Cui},
  title = {{The Dual Role of MicroRNAs in Colorectal Cancer Progression}},
  journal = {International Journal of Molecular Sciences},
  year = {2018},
  doi = {10.3390/ijms19092791},
}
Figure